Exploratory Study of EBV DNA Titre Clearance Whilst on Proton Beam Therapy
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age8-30
SponsorThe Christie NHS Foundation Trust
About this trial
How does plasma Epstein-Barr Virus (EBV) DNA level change during definitive radiation therapy for nasopharyngeal carcinoma (NPC) in the teenage and young adult cohort and does it correlate with outcomes?
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Children and young adults (8-30 years old)
Pathologically confirmed EBV-positive nasopharyngeal carcinoma
Stage I-IVA (AJCC 8th Edition)
Planned to commence curative-intent radiation therapy
Disqualifiers
Recurrent NPC
Concurrent or previously treated EBV-associated malignancy
Prior radiation therapy
Contraindications to MRI
Trial population
Children, teenagers and young adults with nasopharyngeal carcinoma (age 8-30 years old)
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Plasma EBV during proton beam RT
Taken weekly, prior to each session of chemotherapy. Change in plasma EBV DNA levels (EBV VCA-IgM Ab) from each blood sample time point.
Time frame
6 weeksSecondary outcomes
1
EBV and tumour correlates
Taken weekly, prior to each session of chemotherapy. Change in plasma EBV DNA levels (EBV VCA-IgM Ab) from each blood sample. Assessment whether EBV plasma clearance predicts tumour response.
Time frame
2 yearsLocations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: